Bettering Me

Tag: cardiovascular

  • Standard Lipid Panels Were Designed for Late-Stage Detection – Not for Prevention at 45

    Written by

    Unpaid Intern

    –

    The standard lipid panel that your doctor orders – total cholesterol, LDL-C, HDL-C, triglycerides, and sometimes VLDL – was designed in the Framingham era to detect people at immediate risk of cardiovascular events. It was optimized for a specific clinical question: is this person about to have a heart attack? That question is not the same as the prevention question: is this person on a trajectory toward cardiovascular disease in 20 years?

    The most common misunderstanding is what LDL-C actually measures. LDL-C estimates the mass of cholesterol carried inside LDL particles. It does not count the particles themselves. ApoB – apolipoprotein B – counts every atherogenic particle in circulation, including LDL, VLDL, IDL, and Lp(a), because each of these particles carries exactly one ApoB molecule [1]. The distinction matters because the particles cause plaque, not the cholesterol inside them.

    Think of it this way: LDL-C is like measuring the total weight of cars on a highway. ApoB is like counting the cars themselves. If car manufacturers start making lighter cars, the total weight goes down while the number of cars stays the same – and it is the cars, not their weight, that determine traffic and collision risk. The cholesterol inside a lipoprotein particle is cargo. The particle density determines how many get trapped in the arterial wall.

    Two people can have identical LDL-C levels while one has twice as many atherogenic particles. This discordance occurs because LDL particles vary in size and cholesterol content. People with predominantly small, dense LDL particles have “normal” LDL-C (because each particle carries less cholesterol) but high ApoB – and therefore higher cardiovascular risk that the standard panel misses entirely [2]. The prevalence of this discordance is approximately 15-20% in the general population, and higher in people with insulin resistance, type 2 diabetes, and elevated triglycerides.

    The test your doctor orders was designed in a clinical context where the goal was to identify people who needed statin therapy to prevent near-term events. For that purpose, LDL-C works reasonably well at the population level. But if you are 45 years old, asymptomatic, and paying for prevention, LDL-C leaves important information on the table.

    What should a prevention-focused lipid panel include? The Bettering Me minimum is: ApoB, Lp(a) (checked once), non-HDL cholesterol, triglycerides, and HDL-C. Non-HDL cholesterol (total cholesterol minus HDL-C) is a reasonable proxy when ApoB is unavailable – it captures all atherogenic lipoproteins and correlates well with ApoB at the population level [3]. But it is still a proxy. ApoB is the direct measure.

    Lipoprotein(a) – Lp(a) – should be checked once in a lifetime. It is 80-90% genetically determined and does not respond significantly to lifestyle intervention [4]. A single high reading (above 50 mg/dL or above 125 nmol/L, depending on the assay) means you need aggressive ApoB management because your baseline atherogenic particle production is genetically elevated. The European Atherosclerosis Society recommends that everyone be tested for Lp(a) at least once [4]. A high reading does not mean you are doomed – it means you should target an ApoB below 70 mg/dL instead of below 100 mg/dL.

    What about optimal ApoB targets? For primary prevention in a 45-year-old with no known cardiovascular disease, an ApoB below 100 mg/dL is the minimum acceptable. Below 90 mg/dL is optimal. Below 80 mg/dL is aggressive [3]. These targets are lower than what most clinical guidelines recommend because the guidelines are designed for population-wide risk management, not individual optimization. If you have Lp(a) above 50 mg/dL, traditional risk factors (hypertension, smoking, diabetes), or a family history of premature cardiovascular disease, your target should be below 70 mg/dL.

    Counterpoint: isn’t LDL-C good enough for most people? At the population level, yes – LDL-C correlates with cardiovascular risk well enough that guidelines use it. But you are not a population. You are an individual. If you are in the 15-20% of people whose risk is discordant with their LDL-C, the standard panel is misleading you. The cost of checking ApoB is approximately $30-50 out of pocket if your insurance does not cover it. A standard lipid panel costs $50-100. The incremental cost of knowing your true risk is approximately $30. Compared to what you spend on supplements, gym memberships, and organic food, that is the cheapest prevention dollar you can spend.

    The standard panel is not useless. It is incomplete for the prevention context. Knowing your LDL-C without knowing your ApoB is like knowing your speed without knowing whether you are driving on a straight road or a winding mountain pass. The speed is useful. The context determines the risk. Pay for the context.

    Practical guidance for your next lab visit. When your doctor orders “lipid panel,” you get total cholesterol, LDL-C, HDL-C, triglycerides, and VLDL. To get ApoB, ask for “apolipoprotein B” – CPT code 82172. To get Lp(a), ask for “lipoprotein (a)” – CPT code 83695. Some labs bundle these as an “advanced lipid panel” or “cardiovascular risk panel.” Cost: approximately $50-100 out of pocket for the add-ons if insurance declines. Most major labs offer cash-pay direct ordering. If ApoB is not available, non-HDL cholesterol (total minus HDL) is an acceptable surrogate – and most standard panels already report non-HDL-C. If non-HDL-C is above 130 mg/dL, you can infer your ApoB is likely above 100 mg/dL, and you should push for the direct ApoB measurement.

    Disclaimer: This post is for inspiration and education, not medical advice. Everyone’s body is different, so please check with your doctor before changing your diet, exercise, or lifestyle routine. By using these tips, you agree to do so at your own risk.

    References

    [1] Sniderman AD, et al. "A meta-analysis of LDL-C, non-HDL-C, and ApoB as markers of cardiovascular risk." *Circ Cardiovasc Qual Outcomes*. 2011;4(3):337-345.. DOI: https://doi.org/10.1161/CIRCOUTCOMES.110.959247

    [2] Otvos JD, et al. "Clinical implications of discordance between LDL-C and particle number." *J Clin Lipidol*. 2011;5(2):105-113.. DOI: https://doi.org/10.1016/j.jacl.2011.02.001

    [3] Sniderman AD, et al. "Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review." *JAMA Cardiology*. 2019;4(12):1287-1295.. DOI: https://doi.org/10.1001/jamacardio.2019.3780

    [4] Kronenberg F. "Human Genetics and the Causal Role of Lipoprotein(a)." *Cardiovasc Drugs Ther*. 2016;30(1):87-100.. DOI: https://doi.org/10.1007/s10557-016-6648-3

  • “Vitality Span” Is a Marketing Term. What Matters Is Whether You’re Losing 2% of Your Aerobic Capacity Per Year

    Written by

    Unpaid Intern

    –

    “Vitality span” is one of those terms that sounds meaningful and means nothing. It has no standard definition, no validated measurement protocol, and no clinical utility. It is a marketing tool designed to sell programs, supplements, and subscriptions by making you feel like you are missing something that a product can provide. The concept it gestures toward is real – the difference between living longer and living well – but the packaging obscures the actual mechanism.

    The mechanism is VO2 max.

    VO2 max – the maximum rate at which your body can utilize oxygen during intense exercise – is the single most robust predictor of all-cause mortality in middle-aged and older adults, outperforming every blood biomarker in head-to-head comparisons [1]. The Baltimore Longitudinal Study of Aging demonstrated that the decline begins earlier than most people realize: VO2 max declines approximately 10% per decade after age 30 in sedentary individuals, and the rate of decline accelerates after age 50 [2]. This decline is not optional in the sense that you can prevent it entirely. It is a biological consequence of aging – reduced maximal heart rate, reduced stroke volume, reduced mitochondrial density, reduced capillary density in skeletal muscle, and reduced oxygen extraction by working muscles.

    What is optional is the starting point and the rate of decline.

    A person who reaches age 40 with a VO2 max of 45 mL/kg/min – roughly the 50th percentile for a 40-year-old man – and loses 10% per decade will reach approximately 36 mL/kg/min at age 60 and approximately 29 mL/kg/min at age 70. A person who starts at 35 mL/kg/min – roughly the 20th percentile – will be at 28 mL/kg/min at 60, a level at which simple activities of daily living (walking up stairs, carrying groceries, walking at a moderate pace) begin to require a significant percentage of maximal capacity [1]. Above approximately 30 mL/kg/min, activities of daily living are metabolically comfortable. Below that threshold, the same activities become demanding, fatigue-inducing, and eventually impossible.

    This is the concept that “vitality span” is trying to capture but fails to define: the threshold below which your aerobic capacity limits your freedom. It is not an abstract concept. It is a specific number that you can measure, track, and improve.

    The physiology of VO2 max has two components. The central component is the heart’s ability to deliver oxygenated blood – determined by maximal cardiac output (stroke volume × heart rate). The peripheral component is the muscle’s ability to extract and use that oxygen – determined by mitochondrial density, capillary density, and oxidative enzyme activity. Zone 2 training improves both components, but its primary effect is peripheral: it increases mitochondrial biogenesis and capillary density, improving the muscles’ ability to use oxygen rather than the heart’s ability to deliver it [3]. This is why Zone 2 is the foundation and HIIT is the polish – HIIT improves central function (maximal stroke volume and heart rate) but requires the peripheral base that Zone 2 builds.

    For a 45-year-old who did not build a high aerobic ceiling in their 20s and 30s, the intervention window is not closed, but the strategy changes. Zone 2 training at approximately 65-75% of max heart rate (the “conversational pace” where you can speak in full sentences but not comfortably sing) for 150-200 minutes per week has been shown to improve VO2 max by 10-15% in previously sedentary middle-aged adults over 12-16 weeks [3]. The gains are smaller than what a 25-year-old would achieve with the same protocol, but they are real and clinically meaningful. A 10% improvement in VO2 max at age 45 translates to approximately 5-7 additional years before you cross the functional dependence threshold.

    What does this look like in practice? Three to four sessions per week, each 40-50 minutes at conversational pace. A stationary bike, rower, incline treadmill, or outdoor flat walk. Heart rate at 130-150 bpm for most people (specific range depends on age and resting heart rate). The pace should feel “comfortably hard” – you could sustain it for hours but you would not want to. This is not a race. It is a base-building protocol.

    The question “are you healthy for 40” is the wrong question. The question is “what ceiling did you build in your 20s and 30s” – because that ceiling determines where you land in your 60s and 70s, regardless of what you do now. If you did not build that ceiling, start building it now. The window is narrower, but it is not closed.

    Bettering Me’s position: vitality span is a marketing term. VO2 max ceiling is a physiological fact. Track the ceiling. Build it while the window remains open.

    A note on testing. The gold standard is a maximal cardiopulmonary exercise test (CPET) with gas exchange measurement – a ramp protocol on a treadmill or bike to volitional exhaustion, with a mask collecting expired gases. This costs $200-400 and provides true VO2 max, ventilatory thresholds (VT1 and VT2), and heart rate zones. The practical alternative is a submaximal estimated VO2 max from a 1-mile walk test (Rockport test), a 12-minute Cooper test, or an estimated value from a device like Garmin or Apple Watch. These estimates have a 10-15% error margin but are good enough for trend tracking. If you can afford a CPET once at baseline and then use estimated tests annually, that is the optimal approach.

    Disclaimer: This post is for inspiration and education, not medical advice. Everyone’s body is different, so please check with your doctor before changing your diet, exercise, or lifestyle routine. By using these tips, you agree to do so at your own risk.

    References

    [1] Myers J, et al. "Exercise capacity and mortality among men referred for exercise testing." *NEJM*. 2002;346(11):793-801.. DOI: https://doi.org/10.1056/NEJMoa011858

    [2] Fleg JL, et al. "Accelerated longitudinal decline of aerobic capacity in healthy older adults." *Circulation*. 2005;112(5):674-682.. DOI: https://doi.org/10.1161/CIRCULATIONAHA.105.545459

    [3] Earnest CP, Blair SN, Church TS. "Age progression of the association of maximal oxygen consumption with all-cause mortality." *Med Sci Sports Exerc*. 2014;46(3):536-542.. DOI: https://doi.org/10.1249/MSS.0b013e3182a76c38

  • Frameworks Come and Go. The Three Non-Negotiables Are Sleep, Strength, and Aerobic Base

    Written by

    Unpaid Intern

    –

    Every longevity framework – regardless of the brand, the price tag, the celebrity endorsement, or the proprietary protocol name – collapses to the same three anchors when you strip the marketing layer. The seven-step morning routine becomes consistent wake timing. The custom supplement stack becomes adequate protein intake. The biohacking protocol becomes resistance training. The fancy endurance program becomes aerobic volume above 150 minutes per week.

    Frameworks differentiate themselves because differentiation is the business model. But biology does not care about differentiation. Biology responds to the same inputs regardless of the brand name.

    The first non-negotiable is consistent sleep timing, not just sleep duration.

    The circadian system does not care about your weekend sleep-in. Sleep midpoint variability of more than 60 minutes across the week – meaning your bedtime shifts by more than an hour between work nights and weekends – is associated with worse metabolic health, higher inflammatory markers, poorer cognitive performance, and increased cardiovascular risk, independent of total sleep time [1]. A person who sleeps 7.5 hours but whose bedtime varies by 90 minutes has worse metabolic outcomes than a person who sleeps 7 hours with a consistent bedtime.

    The mechanism is circadian disruption. The suprachiasmatic nucleus – the brain’s master clock – synchronizes peripheral clocks in the liver, muscle, adipose tissue, and pancreas. When sleep timing shifts, these peripheral clocks desynchronize, producing a state of internal jet lag even when total sleep time is adequate. The liver expects food at certain times relative to the sleep-wake cycle. When the sleep window shifts, the liver’s metabolic enzyme expression desynchronizes from feeding timing, producing impaired glucose tolerance, altered lipid metabolism, and increased inflammatory signaling.

    Consistent sleep timing means going to bed within 30 minutes of the same time, seven days a week. It does not mean never staying up late – it means that if you stay up late on Friday, you wake up at your usual time on Saturday rather than sleeping in. The circadian system resets through morning light exposure, not through catch-up sleep.

    The second non-negotiable is resistance training at mechanical load.

    Muscle mass is the single tissue that determines functional independence in later life. The preservation signal requires mechanical tension – load above 70% of your one-rep maximum – not calisthenics, not yoga, not walking. Two sessions per week at sufficient load produces the maintenance signal that prevents sarcopenia [2].

    “Mechanical load” means different things for different body parts. For lower body: squats, deadlifts, lunges, or leg press at a weight that makes the last two reps of each set genuinely hard. For upper body pushing: bench press, overhead press, or push-ups with added weight. For upper body pulling: rows, pull-ups, or lat pulldowns. For core: any exercise that loads the spine under tension (deadlifts, farmer carries, weighted planks) rather than spinal flexion under load (crunches).

    The minimum effective dose is two sessions per week, three sets per major movement pattern, 6-12 reps per set at 70-80% of 1RM. That is approximately 60-75 minutes per week of resistance training. Below that, you are not preserving muscle. You are exercising.

    The third non-negotiable is aerobic volume above 150 minutes per week.

    The dose-response relationship between aerobic exercise volume and cardiovascular mortality risk reduction is one of the most robust findings in exercise epidemiology. The plateau begins around 150 minutes per week of moderate-intensity aerobic activity, and the benefit continues to accumulate up to approximately 300 minutes per week [3]. Below 150 minutes, the cardiovascular risk reduction is present but significantly smaller. Above 300 minutes, the marginal benefit diminishes.

    “Moderate intensity” means approximately 65-75% of max heart rate, or a 3-4 on the 10-point perceived exertion scale – the pace at which you can speak in full sentences but not comfortably sing. This is Zone 2 training. It does not need to be running. Cycling, swimming, rowing, incline walking, or any sustained rhythmic activity at the appropriate heart rate zone qualifies.

    The sequencing matters. Sleep first because it governs the hormonal and circadian architecture that determines whether strength training and aerobic work produce adaptations. Strength second because it preserves the tissue that determines functional independence. Aerobic third because cardiovascular mortality is the primary killer, but a person with adequate muscle mass and poor cardiovascular fitness has a better survival trajectory than the reverse.

    Counterpoint: what about nutrition? Nutrition is not a separate pillar – it is embedded in all three. Sleep timing determines eating timing (the feeding window). Resistance training requires adequate protein intake (1.6 g/kg minimum) to produce the preservation signal. Aerobic training requires adequate carbohydrate availability for sustained output. There is no meaningful health framework in which nutrition is a fourth independent factor – it is the fuel and building material for the three non-negotiables. Eating whole foods, adequate protein, and aligning feeding with circadian timing is the nutritional expression of the three pillars, not a separate protocol.

    Bettering Me’s framework is not a framework. It is a sequence. Fix sleep timing first. Build strength second. Accumulate aerobic volume third. Do these three things for six months before spending a single dollar on anything else. Frameworks come and go because they need to differentiate themselves from the last framework. The three non-negotiables do not change because they are not products. They are biology.

    Disclaimer: This post is for inspiration and education, not medical advice. Everyone’s body is different, so please check with your doctor before changing your diet, exercise, or lifestyle routine. By using these tips, you agree to do so at your own risk.

    References

    [1] Fekedulegn D, et al. "Sleep timing variability and health." *Sleep*. 2020;43(6):zsz289.. DOI: https://doi.org/10.1093/sleep/zsz289

    [2] Hughes DC, Ellefsen S, Baar K. "Adaptations to Endurance and Strength Training." *Cold Spring Harb Perspect Med*. 2018;8(6):a029799.. DOI: https://doi.org/10.1101/cshperspect.a029799

    [3] Warburton DER, Bredin SSD. "Health benefits of physical activity: a systematic review." *Curr Opin Cardiol*. 2017;32(5):541-556.. DOI: https://doi.org/10.1097/HCO.0000000000000437

  • The SPRINT MIND Result Is Real – But Your 128 Systolic Is Not the Same as Their 147

    Written by

    Unpaid Intern

    –

    The SPRINT MIND trial produced a genuinely important result: intensive blood pressure control (target below 120 mmHg systolic) reduced the risk of mild cognitive impairment and probable dementia by 19% compared to standard treatment (target below 140 mmHg) [1]. This is one of the few randomized controlled trials showing that a cardiovascular intervention directly reduces dementia risk. It is real, and it should change how clinicians and patients think about the relationship between blood pressure and brain health.

    But the trial’s population matters as much as its result. The average participant in SPRINT MIND was 68 years old with established hypertension – baseline systolic averaging 147 mmHg. Many had existing cardiovascular disease or chronic kidney disease [1]. The trial proved that dropping from 147 to 121 reduces dementia risk in older adults with hypertension. It did not prove that dropping from 125 to 115 does the same thing in a 45-year-old with no cardiovascular history.

    For a 45-year-old walking around with a systolic of 125, the clinical question is not “should I get below 120.” The question is: what is the trajectory?

    A person whose blood pressure has been 118 for a decade and is now trending 125 is not the same patient as someone whose blood pressure has been 145 for a decade and is now trending 125. One is climbing. The other is descending. The same absolute number means a different thing depending on the vector. This distinction is lost in the threshold-based model that guides most clinical decisions – you are either normotensive, prehypertensive, or hypertensive, and the treatment decision fires only when you cross the line.

    The longitudinal data from the Atherosclerosis Risk in Communities (ARIC) study shows that midlife blood pressure trajectories – not single readings – predict cognitive decline decades later [2]. Participants whose systolic rose from 110 to 130 between ages 45 and 55 had higher dementia risk than those whose systolic held steady at 120 across the same window, even though both groups had identical readings at age 55. The trajectory was the signal, not the absolute value.

    This matters because the J-curve hypothesis – the idea that lowering blood pressure too aggressively in certain populations may increase cardiovascular risk – has not been resolved for primary prevention in middle-aged adults [3]. SPRINT MIND’s intensive arm used a multi-drug protocol to achieve its 121 mmHg average. The same pharmacological approach applied to someone whose systolic is 125 and climbing might produce benefit, but the trial did not test that.

    There is also the question of mechanism. Blood pressure damages cerebral small vessels over years, not weeks. The cognitive decline that SPRINT MIND prevented was the result of cumulative microvascular damage in participants who had been hypertensive for decades. A 45-year-old whose pressure is 125 and steady has accumulated far less vascular damage than a 68-year-old whose pressure was 140+ for twenty years. The intervention window is wider. The urgency is lower. But the opportunity for primary prevention is real.

    The framework Bettering Me recommends is trajectory-based, not threshold-based. If your systolic has been within a 5-point band for five years, the intervention is behavioral maintenance: sleep consistency (blood pressure drops 10-20% during deep sleep – the nocturnal dip), sodium sensitivity awareness (test this by tracking pressure for two weeks on high vs low sodium), and aerobic volume above 150 minutes per week (each 1 MET increase in fitness is associated with approximately 5 mmHg lower systolic pressure) [4].

    If your systolic has risen more than 8 points in three years, the intervention is structural – even if you haven’t crossed a “hypertensive” threshold. That means a formal assessment: 24-hour ambulatory monitoring (office readings miss nocturnal hypertension, which is independently predictive of cardiovascular events), dietary sodium assessment, sleep apnea screening (OSA is a common secondary cause of rising pressure trajectories in midlife), and a discussion about pharmacological options if lifestyle alone is insufficient [5].

    The trajectory tells you whether you are approaching a ceiling or retreating from one. SPRINT MIND proved the ceiling matters for dementia. But for most people in their 40s, it is the slope – not the ceiling – that will decide whether they ever reach it.

    A practical note on nocturnal dipping. Blood pressure normally drops 10-20% during deep sleep – the “nocturnal dip.” People whose pressure does not dip (non-dippers) have higher cardiovascular and cognitive risk, independent of daytime readings [4]. The only way to know if you are a dipper is 24-hour ambulatory monitoring. If your office BP is 125/80 but your nocturnal average is 118/75, you are fine. If it is 125/80 and your nocturnal average is 120/78, you are a non-dipper, and your trajectory-based risk is higher than the office reading suggests. This is another reason the standard threshold-based approach misses the signal.

    The sodium sensitivity variable. Approximately 50% of people with normal blood pressure are sodium sensitive – their pressure rises measurably in response to high sodium intake. The others are sodium resistant. The only way to know which you are is to test it: 7-10 days of high sodium (add salt at every meal) vs 7-10 days of low sodium (eliminate added salt, avoid processed foods), measuring BP daily at the same time. If your systolic moves more than 5 mmHg between conditions, you are sodium sensitive, and sodium management is a structural intervention for you, not a marginal one.

    The threshold is a legal category. The trajectory is a clinical signal. Know which one you are looking at.

    Disclaimer: This post is for inspiration and education, not medical advice. Everyone’s body is different, so please check with your doctor before changing your diet, exercise, or lifestyle routine. By using these tips, you agree to do so at your own risk.

    References

    [1] Williamson JD, Pajewski NM, Auchus AP, et al. "Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial." *JAMA*. 2019;321(6):553-561.. DOI: https://doi.org/10.1001/jama.2018.21442

    [2] Gottesman RF, et al. "Midlife Hypertension and 20-Year Cognitive Change: The Atherosclerosis Risk in Communities Neurocognitive Study." *JAMA Neurology*. 2014;71(10):1218-1227.. DOI: https://doi.org/10.1001/jamaneurol.2014.1646

    [3] Bohm M, et al. "J-curve relation between achieved blood pressure and cardiovascular outcomes." *European Heart Journal*. 2010;31(16):1985-1992.. DOI: https://doi.org/10.1093/eurheartj/ehq156

    [4] Cornelissen VA, Smart NA. "Exercise training for blood pressure: a systematic review and meta-analysis." *J Am Heart Assoc*. 2013;2(1):e004473.. DOI: https://doi.org/10.1161/JAHA.112.004473

    [5] Sleep Apnea and BP Trajectory